Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$29.28
+1.7%
$24.04
$6.45
$37.38
$547.35M0.95676,553 shs405,032 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
+1.74%+8.65%+23.81%+164.00%+56.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
4.2864 of 5 stars
3.44.00.04.22.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.86
Moderate Buy$88.33201.68% Upside

Current Analyst Ratings Breakdown

Latest NKTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $85.00
6/24/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$60.00 ➝ $100.00
6/24/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$120.00
(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$98.43M5.66N/AN/A($1.27) per share-23.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$118.96M-$8.80N/AN/AN/A-163.17%-631.43%-58.21%11/6/2025 (Estimated)

Latest NKTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$3.13-$2.95+$0.18-$2.95$9.42 million$11.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
2.61
2.61

Institutional Ownership

CompanyInstitutional Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%

Insider Ownership

CompanyInsider Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
5.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
22019.02 million18.02 millionOptionable

Recent News About These Companies

Nektar (NKTR) Q2 Revenue Falls 52%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$29.28 +0.50 (+1.74%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$29.08 -0.20 (-0.67%)
As of 04:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.